- Trials with a EudraCT protocol (43)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
43 result(s) found for: Working Formulation.
Displaying page 1 of 3.
| EudraCT Number: 2013-004054-21 | Sponsor Protocol Number: CC-5013-DLC-002 | Start Date*: 2014-09-26 | ||||||||||||||||||||||||||
| Sponsor Name:Celgene Corporation | ||||||||||||||||||||||||||||
| Full Title: Phase 3 Randomized, Double-Blind, Placebo Controlled, Multicenter Study to Compare the Efficacy and Safety of Lenalidomide (CC-5013) Plus R-CHOP Chemotherapy (R2-CHOP) Versus Placebo Plus R-CHOP Ch... | ||||||||||||||||||||||||||||
| Medical condition: Previously untreated, activated B-cell (ABC) type diffuse large B-cell lymphoma (DLBCL). | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
| Trial protocol: ES (Ongoing) IE (Completed) CZ (Completed) IT (Completed) PT (Completed) BE (Completed) NL (Completed) | ||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||
| EudraCT Number: 2020-003876-42 | Sponsor Protocol Number: SAKK38/19 | Start Date*: 2022-04-29 | |||||||||||
| Sponsor Name:SAKK | |||||||||||||
| Full Title: Assessing a ctDNA and PET-oriented therapy in patients with DLBCL. A multicenter, open-label, phase II trial | |||||||||||||
| Medical condition: Disseminated large B cell lymphoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2018-003727-10 | Sponsor Protocol Number: MO40598 | Start Date*: 2019-12-16 | |||||||||||||||||||||
| Sponsor Name: Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F.Hoffmann-La Roche Ltd | |||||||||||||||||||||||
| Full Title: A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY EVALUATING THE SAFETY AND EFFICACY OF POLATUZUMAB VEDOTIN IN COMBINATION WITH RITUXIMAB PLUS GEMCITABINE PLUS OXALIPLATIN (R-GEMOX) VERSUS R-G... | |||||||||||||||||||||||
| Medical condition: Relapsed/refractory diffuse large B-cell lymphoma (DLBL) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: ES (Ongoing) FR (Trial now transitioned) GB (GB - no longer in EU/EEA) IE (Completed) FI (Completed) SE (Completed) IT (Trial now transitioned) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2015-001999-22 | Sponsor Protocol Number: GO29834 | Start Date*: 2016-02-25 | |||||||||||||||||||||
| Sponsor Name:F. Hoffmann-La Roche Ltd. | |||||||||||||||||||||||
| Full Title: A PHASE Ib/II STUDY EVALUATING THE SAFETY AND EFFICACY OF OBINUTUZUMAB IN COMBINATION WITH POLATUZUMAB VEDOTIN AND LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR OR DIFFUSE LARGE B... | |||||||||||||||||||||||
| Medical condition: Relapsed or refractory, follicular lymphoma (FL) or diffuse large B-cell lymphoma (DLBCL) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: ES (Completed) | |||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||
| EudraCT Number: 2015-001998-40 | Sponsor Protocol Number: GO29833 | Start Date*: 2016-03-01 | |||||||||||||||||||||
| Sponsor Name:F. HOFFMANN - LA ROCHE LTD. | |||||||||||||||||||||||
| Full Title: A PHASE Ib/II STUDY EVALUATING THE SAFETY AND EFFICACY OF OBINUTUZUMAB IN COMBINATION WITH POLATUZUMAB VEDOTIN AND VENETOCLAX IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA AND RITUXIM... | |||||||||||||||||||||||
| Medical condition: Relapsed or refractory, follicular lymphoma (FL) or diffuse large B-cell lymphoma (DLBCL) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||
| EudraCT Number: 2011-004377-84 | Sponsor Protocol Number: GO27834 | Start Date*: 2013-04-11 | ||||||||||||||||||||||||||
| Sponsor Name:Genentech, Inc. | ||||||||||||||||||||||||||||
| Full Title: A randomized, open-label, multicenter, phase II trial evaluating the safety and activity of pinatuzumab vedotin (DCDT2980S) in combination with rituximab or polatuzumab vedotin (DCDS4501A) in combi... | ||||||||||||||||||||||||||||
| Medical condition: Follicular Non-Hodgkin’s Lymphoma (FL); Diffuse Large B-Cell Lymphoma (DLBCL) | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
| Trial protocol: DE (Completed) IT (Completed) NL (Completed) FR (Completed) | ||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||
| EudraCT Number: 2015-005837-37 | Sponsor Protocol Number: 15-201 | Start Date*: 2016-03-15 | |||||||||||
| Sponsor Name:CHU CAEN | |||||||||||||
| Full Title: ASSOCIATION RITUXIMAB - BENDAMUSTINE - ARACYTINE DANS LE TRAITEMENT DES LYMPHOMES B DIFFUS À GRANDES CELLULES REFRACTAIRES OU EN RECHUTE : ETUDE DE PHASE II | |||||||||||||
| Medical condition: Patients atteints de lymphome B diffus à grandes cellules en rechute ou réfractaires | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2008-005496-10 | Sponsor Protocol Number: H6Q-MC-S028 | Start Date*: 2009-01-28 | |||||||||||
| Sponsor Name:Eli Lilly and Company | |||||||||||||
| Full Title: An Open-label, Randomized, Phase 2 Study of R-CHOP Plus Enzastaurin versus R-CHOP in the First-Line Treatment of Patients with Intermediate and High-Risk Diffuse Large B-Cell Lymphoma | |||||||||||||
| Medical condition: First-Line Diffuse Large B-Cell Lymphoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IE (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2020-000605-84 | Sponsor Protocol Number: XPORT-DLBCL-030 | Start Date*: 2020-09-16 | ||||||||||||||||
| Sponsor Name:Karyopharm Therapeutics Inc. | ||||||||||||||||||
| Full Title: A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR DL... | ||||||||||||||||||
| Medical condition: Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR DLBCL) | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: AT (Ongoing) FR (Ongoing) IT (Trial now transitioned) GR (Completed) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2014-001361-28 | Sponsor Protocol Number: GO29365 | Start Date*: 2015-10-07 | |||||||||||||||||||||
| Sponsor Name:F. Hoffmann-La Roche Ltd. | |||||||||||||||||||||||
| Full Title: A Phase Ib/II study evaluating the safety, tolerability and anti-tumor activity of polatuzumab vedotin in combination with rituximab (R) or obinutuzumab (G) plus bendamustine (B) in relapsed or ref... | |||||||||||||||||||||||
| Medical condition: Follicular Lymphoma and Diffuse Large B-Cell Lymphoma | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: CZ (Completed) HU (Completed) DE (Completed) GB (GB - no longer in EU/EEA) ES (Ongoing) NL (Completed) FR (Ongoing) IT (Completed) | |||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||
| EudraCT Number: 2018-003889-14 | Sponsor Protocol Number: NLG-LBC7 | Start Date*: 2020-04-07 | |||||||||||
| Sponsor Name:Skåne University Hospital, Department of Oncology | |||||||||||||
| Full Title: R-MINI-CHOP versus R-MINI-CHP in combination with polatuzumab-vedotin, as primary treatment for patients with diffuse large B-cell lymphoma, ≥80 years, or frail ≥75 years – an open label randomized... | |||||||||||||
| Medical condition: Diffuse large B-cell lymphoma. | |||||||||||||
|
|||||||||||||
| Population Age: Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: SE (Trial now transitioned) NO (Trial now transitioned) DK (Trial now transitioned) FI (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2007-002414-19 | Sponsor Protocol Number: | Start Date*: 2008-05-22 | |||||||||||
| Sponsor Name:GOELAMS | |||||||||||||
| Full Title: Etude prospective multicentrique de phase II évaluant la radioimmunothérapie fractionnée avec un anticorps humanisé anti-CD22 marqué à l'yttrium 90 (90Y-DOTA-hLL2) en consolidation après immuno-chi... | |||||||||||||
| Medical condition: lymphomes B agressifs disséminés du sujet de plus de 60 ans et de moins de 80 ans. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2020-004977-38 | Sponsor Protocol Number: VERLEN | Start Date*: 2021-07-08 | |||||||||||
| Sponsor Name:LYSARC | |||||||||||||
| Full Title: Phase II, Open-Label Study evaluating efficacy of Tafasitamab and Lenalinomide associated to Rituximab in frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or older | |||||||||||||
| Medical condition: Frontline DLBCL | |||||||||||||
|
|||||||||||||
| Population Age: Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Trial now transitioned) BE (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2015-005273-20 | Sponsor Protocol Number: FIL-GALILEO | Start Date*: 2016-02-11 | |||||||||||
| Sponsor Name:FONDAZIONE ITALIANA LINFOMI ONLUS | |||||||||||||
| Full Title: Multicenter phase II single arm open-label study on the feasibility, safety and efficacy of combination of CHOP-21 supplemented with Obinutuzumab and Ibrutinib in untreated young high risk Diffus... | |||||||||||||
| Medical condition: Diffuse Large B-Cell lymphoma (DLBCL) | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2016-003703-62 | Sponsor Protocol Number: FIL_DEVEC | Start Date*: 2017-04-27 | |||||||||||
| Sponsor Name:FONDAZIONE ITALIANA LINFOMI ONLUS | |||||||||||||
| Full Title: A phase II study of metronomic chemotherapy in elderly non-fit patients (>65 years) with aggressive B-Cell lymphomas. | |||||||||||||
| Medical condition: B-Cell lymphomas | |||||||||||||
|
|||||||||||||
| Population Age: Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2017-002023-21 | Sponsor Protocol Number: GO39942 | Start Date*: 2018-08-31 | |||||||||||
| Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
| Full Title: A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL COMPARING THE EFFICACY AND SAFETY OF POLATUZUMAB VEDOTIN IN COMBINATION WITH RITUXIMAB AND CHP (R-CHP) VERSUS RITUXIMAB ... | |||||||||||||
| Medical condition: Diffuse large B-cell lymphoma (DLBCL) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Trial now transitioned) CZ (Trial now transitioned) PT (Completed) BE (Trial now transitioned) AT (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) GB (GB - no longer in EU/EEA) IT (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2018-001141-13 | Sponsor Protocol Number: GO40516 | Start Date*: 2020-02-21 | |||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||||||||||||||||||||||||||||||||
| Full Title: AN OPEN-LABEL, RANDOMIZED, MULTICENTER, PHASE Ib/II TRIAL EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF MOSUNETUZUMAB (BTCT4465A) IN COMBINATION WITH POLATUZUMAB VEDOTIN IN... | |||||||||||||||||||||||||||||||||||||||||||
| Medical condition: B-cell non-Hodgkin lymphoma (NHL) | |||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: DE (Prematurely Ended) ES (Ongoing) BE (Trial now transitioned) | |||||||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2010-019575-29 | Sponsor Protocol Number: CLL210Version10 | Start Date*: 2011-04-15 | ||||||||||||||||
| Sponsor Name:University of Liverpool [...] | ||||||||||||||||||
| Full Title: Phase II trial of ofatumumab, dexamethasone and lenalidomide for high-risk CLL (NCRI CLL210) | ||||||||||||||||||
| Medical condition: Chronic lymphocytic leukaemia / Small Lymphocytic Lymphoma | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: GB (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2021-003313-18 | Sponsor Protocol Number: MK-2140-003 | Start Date*: 2022-01-10 | |||||||||||
| Sponsor Name:Merck Sharp & Dohme LLC | |||||||||||||
| Full Title: A Phase 2/3 Multicenter, Open-label, Randomized, Active-Control Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Larg... | |||||||||||||
| Medical condition: Treatment of participants with Relapsed or Refractory Diffuse Large B-Cell Lymphoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: PL (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2018-001366-42 | Sponsor Protocol Number: BGB-3111-305 | Start Date*: 2018-11-07 | ||||||||||||||||
| Sponsor Name:BeiGene, Ltd. | ||||||||||||||||||
| Full Title: A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared with Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | ||||||||||||||||||
| Medical condition: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: FR (Completed) ES (Completed) BE (Completed) CZ (Completed) GB (GB - no longer in EU/EEA) SE (Completed) NL (Completed) IT (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.
